Listed by the USPTO as HELM, CARALYNNE E
Tech Center 1600 • Art Units: 1615
This examiner grants 29% of resolved cases
HELM, CARALYNNE E examines in Tech Center 1600 and Art Unit 1615. Her record includes 805 resolved cases, with a 28.9% allowance rate. Interview lift is 49.9%, a substantial reported association relative to the underlying allowance result, so interview preparation may be important when a case is positioned for reconsideration.
The median time to allowance is 1497 days, indicating a lengthy path in the reported record. Practitioners may need to plan for sustained prosecution and preserve clear claim distinctions through multiple response stages. The leading companies are Spiral Therapeutics Inc., L'Oréal, and Nestlé S.A. The principal firms are FISH & RICHARDSON P.C. (TC), K&L Gates LLP-Nestec S.A., and Apex Attorneys at Law, LLP.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19530028 | GELLING SOLUTIONS FOR ADMINISTRATION OF COMPOUNDS TO THE INNER EAR | Final Rejection | Spiral Therapeutics, Inc. |
| 19463990 | GELLING SOLUTIONS FOR ADMINISTRATION OF COMPOUNDS TO THE INNER EAR | Non-Final OA | Spiral Therapeutics, Inc. |
| 19459988 | GELLING SOLUTIONS FOR ADMINISTRATION OF COMPOUNDS TO THE INNER EAR | Final Rejection | Spiral Therapeutics Inc. |
| 17923945 | GELLING SOLUTIONS FOR ADMINISTRATION OF COMPOUNDS TO THE INNER EAR | Non-Final OA | Spiral Therapeutics Inc. |
| 18423951 | SURGICAL SYSTEM AND METHODS OF USE | Non-Final OA | Medtronic, Inc. |
| 18678709 | MARIBAVIR COMPOSITIONS AND USES THEREOF | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18254312 | RAPIDLY RESORBABLE INTRAVASCULAR IMPLANT | Non-Final OA | BIOTRONIK AG |
| 19374982 | ORAL SOLID DOSAGE FORMS COMPRISING CANNABINOIDS | Non-Final OA | Jazz Pharmaceuticals Research UK Limited |
| 17740607 | COMPOSITIONS AND METHODS USING A COMBINATION OF CALCIUM AND AT LEAST ONE OF OLEUROPEIN OR METABOLITE THEREOF | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 17595159 | COMPOSITIONS AND METHODS USING A COMBINATION OF CALCIUM AND AT LEAST ONE OF OLEUROPEIN OR METABOLITE THEREOF | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18029619 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMPLANT ASSOCIATED COMPLICATIONS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 19195301 | HARD SURFACE CLEANING SOLUTION WITH RAPID VIRICIDAL ACTIVITY | Non-Final OA | ECOLAB USA INC. |
| 17556093 | DUAL AGENT NANOPARTICLE COMPOSITION FOR COATING MEDICAL DEVICES | Non-Final OA | THE CLEVELAND CLINIC FOUNDATION |
| 18918858 | METHOD OF MAKING AN OSTEOCONDUCTIVE FIBROUS ARTICLE AND A MEDICAL IMPLANT COMPRISING SUCH OSTEOCONDUCTIVE FIBROUS ARTICLE | Non-Final OA | DSM IP Assets B.V. |
| 18877255 | STABILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME | Non-Final OA | L'OREAL |
| 18602424 | PROCESS FOR COLOURING A BASE COSMETIC COMPOSITION | Final Rejection | L'Oreal |
| 18580525 | COMPOSITION COMPRISING A SPECIFIC COMBINATION OF SURFACTANTS AND A CATIONIC POLYMER | Non-Final OA | L'Oreal |
| 18543756 | COMPOSITIONS CONTAINING BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE AND AVOBENZONE | Final Rejection | L'OREAL |
| 18688413 | BIOACTIVE GLASS COMPOSITIONS AND METHODS OF TREATMENT | Final Rejection | The Curators of the University of Missouri |
| 17629639 | WATER BASED COMPOSITION | Final Rejection | Shiseido Company, Ltd. |
| 18700520 | COMPOSITIONS FOR DELIVERY OF CANNABINOIDS | Non-Final OA | PNEUMA RESPIRATORY, INC. |
| 18091615 | OPTICALLY CLEAR, IN-SITU FORMING BIODEGRADABLE NANO-CARRIERS FOR OCULAR THERAPY, AND METHODS USING SAME | Final Rejection | Rowan University |
| 17392361 | REACTOR FOR PRODUCING PHARMACEUTICAL PARTICLES IN A PRECIPITATION PROCESS | Final Rejection | MannKind Corporation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy28.9% of resolved applications examined by Caralynne E Helm were allowed (805 resolved cases), compared with 43.8% across Art Unit 1615 over the last five years.
This examiner's interview lift is +49.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Caralynne E Helm took 1,497 days on average from filing to allowance.
Caralynne E Helm examines applications in Art Unit 1615 in Tech Center 1600 (Biotechnology & Pharmaceuticals).